Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLIPS trial of benralizumab in children with eosinophilic diseases
2023-508533-14-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 10
01
Overview
Phase 3, open-label trial of benralizumab in eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES) (2 cohorts), sponsored by AstraZeneca. Planned start Jul 2026; status: authorised.
02
Drugs
benralizumab
03
Conditions
eosinophilic granulomatosis with polyangiitis (EGPA)hypereosinophilic syndrome (HES)
Beyond the preview
Go deeper on 2023-508533-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508533-14-00.